Hwang Hee Sang, Yoon Dok Hyun, Suh Cheolwon, Park Chan-Sik, Huh Jooryung
Department of Pathology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea.
Department of Oncology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea.
Blood Res. 2013 Dec;48(4):266-73. doi: 10.5045/br.2013.48.4.266. Epub 2013 Dec 24.
Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous clinicopathological entity, and its molecular classification into germinal center B cell-like (GCB) and activated B cell-like (ABC) subtypes using gene expression profile analysis has been shown to have prognostic significance. Recent attempts have been made to find an association between immunohistochemical findings and molecular subgroup, although the clinical utility of immunohistochemical classification remains uncertain.
The clinicopathological features and follow-up data of 68 cases of surgically resected gastrointestinal DLBCL were analyzed. Using the immunohistochemical findings on tissue microarray, the cases were categorized into GCB and non-GCB subtypes according to the algorithms proposed by Hans, Muris, Choi, and Tally.
The median patient age was 56 years (range, 26-77 years). Of the 68 cases included, 39.7% (27/68) involved the stomach, and 60.3% (41/68) involved the intestines. The GCB and non-GCB groups sorted according to Hans, Choi, and Tally algorithms, but not the Muris algorithm, were closely concordant (Hans vs. Choi, κ=0.775, P<0.001; Hans vs. Tally, κ=0.724, P<0.001; Choi vs. Tally, κ=0.528, P<0.001). However, there was no prognostic difference between the GCB and non-GCB subtypes, regardless of the algorithm used. On univariate survival analyses, international prognostic index risk group and depth of tumor invasion both had prognostic significance.
The Hans, Choi, and Tally algorithms might represent identical DLBCL subgroups, but this grouping did not correlate with prognosis. Further studies may delineate the association between immunohistochemical subgroups and prognosis.
弥漫性大B细胞淋巴瘤(DLBCL)是一种异质性的临床病理实体,通过基因表达谱分析将其分子分类为生发中心B细胞样(GCB)和活化B细胞样(ABC)亚型已显示出具有预后意义。尽管免疫组织化学分类的临床实用性仍不确定,但最近已尝试寻找免疫组织化学结果与分子亚组之间的关联。
分析68例手术切除的胃肠道DLBCL的临床病理特征和随访数据。利用组织微阵列上的免疫组织化学结果,根据Hans、Muris、Choi和Tally提出的算法将病例分为GCB和非GCB亚型。
患者中位年龄为56岁(范围26 - 77岁)。在纳入的68例病例中,39.7%(27/68)累及胃,60.3%(41/68)累及肠道。根据Hans、Choi和Tally算法分类的GCB和非GCB组,但不包括Muris算法,密切一致(Hans与Choi,κ = 0.775,P < 0.001;Hans与Tally,κ = 0.724,P < 0.001;Choi与Tally,κ = 0.528,P < 0.001)。然而,无论使用何种算法,GCB和非GCB亚型之间均无预后差异。单因素生存分析显示,国际预后指数风险组和肿瘤浸润深度均具有预后意义。
Hans、Choi和Tally算法可能代表相同的DLBCL亚组,但这种分组与预后无关。进一步的研究可能会阐明免疫组织化学亚组与预后之间的关联。